Citations

Mayo Clinic

Showing 10 of 108572 citations.

Effects of hearing intervention on cognitive decline: Results of the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized trial
Lin, Frank R. , Albert, Marilyn S. , Burgard, Sheila , Gmelin, Theresa , Gravens‐Mueller, Lisa, Huang, Alison , Mosley, Thomas H., Reed, Nicholas S. , Windham, B. Gwen , Pike, James Russell , Arnold, Michelle L. , Chisolm, Theresa Hnath , Couper, David , Deal, Jennifer A. , Goman, Adele M. , Glynn, Nancy W. , Hayden, Kathleen M. , Knopman, David S. , MITCHELL, CHRISTINE M. , Pankow, James S. , Sanchez, Victoria A , Schrack, Jennifer A. , Coresh, Josef

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.083084 Get It

AbstractBackgroundHearing loss is associated with greater cognitive decline and incident dementia. Whether hearing intervention could reduce cognitive decline in older adults with hearing loss is unknown.MethodThe ACHIEVE study is a randomized trial (NCT03243422) of 70‐84 year‐old adults with untreated hearing loss and free from substantial cognitive impairment that took place at four U.S. sites. Participants were recruited from two study populations: 1) a group of adults participating in a longstanding observational study of cardiovascular health (Atherosclerosis Risk in Communities [ARIC] study), and 2) a group of healthy de novo community volunteers. Participants were randomised (1:1) to hearing intervention (HI; audiological counseling and provision of hearing aids) or a successful aging health education control intervention (SA; sessions with a health educator on chronic disease prevention). The primary intention‐to‐treat endpoint was 3‐year change in a global cognition standardized factor score from a comprehensive neurocognitive battery.Result977 participants (238 ARIC, 739 de novo) underwent randomisation; 490 were assigned to HI and 487 to SA control. Participants from ARIC were older, had more risk factors for cognitive decline, and had lower baseline cognitive scores than the de novo group. In the primary analysis combining the ARIC and de novo groups, 3‐year cognitive change (in S.D. units) was not significantly different between HI and SA control (HI: ‐0·200 [95% CI: ‐0·256,‐0·144]; SA: ‐0·202 [‐0·258,‐0·145]; Difference 0·002 [‐0·077,0·081],p = 0·96). However, prespecified analyses demonstrated significant differences in the effect of HI on cognitive change between the ARIC and de novo group (p interaction = 0·010). In the ARIC group, HI was associated with a 48% reduction in 3‐year cognitive change compared to SA control (HI: ‐0·211 [‐0·349,‐0·073]; SA: ‐0·402 [‐0·536, ‐0·267]; Difference 0·191 [0·022,0·360,p = 0·027]). In the de novo group, cognitive change was not significantly different between HI and SA control (HI: ‐0·213 [‐0·277,‐0·148]; SA: ‐0·151 [‐0·215,‐0·087]; Difference ‐0·061 [‐0·151,0·028,p = 0·18]). The rate of cognitive change among control participants was observed to be 2.7‐fold faster in the ARIC versus de novo group.ConclusionHearing intervention may have a significant effect on reducing cognitive change over 3 years in populations of older adults at increased risk for cognitive decline.
Cognitive Clusters of Early‐onset non‐Alzheimer’s disease
Kim, Hee Jin , Lane, Kathleen A. , Gao, Sujuan , Hammers, Dustin B. , Aisen, Paul , Eloyan, Ani , Iaccarino, Leo, Kramer, Joel H. , Rumbaugh, Malia, Soleimani‐Meigooni, David N. , Taurone, Alexander, Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan C., Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Dickerson, Brad C., Apostolova, Liana G. , Hammers, Dustin B , Logan, Paige E. , Dage, Jeffrey L. , Foroud, Tatiana , Grinberg, Lea T. , Jack, Clifford R. , Koeppe, Robert A. , Kukull, Walter A. , Joie, Renaud La , Mundada, Nidhi S. , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Vemuri, Prashanthi , Atri, Alireza , Day, Gregory S. , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Carrillo, María C. , Rabinovici, Gil D.

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.083061 Get It

AbstractBackgroundApproximately 10‐25% of amnestic early‐onset dementia are negative for amyloid (Early‐onset non‐Alzheimer’s Disease, EOnonAD). EOnonAD is a heterogenous group with various etiologies. In order to better understand the traits of EOnonAD, we clustered amnestic EOnonAD individuals according to cognitive patterns.MethodCognitive data of 62 EOnonAD individuals from the Longitudinal Early‐onset AD study (LEADS) were Z‐normalized to 91 intact individuals after adjusting for age, sex, and education. This led to domain‐averaged composite Z‐scores for memory, language, speed/attention, visuospatial, and executive function. Cluster analysis using the Ward method on the residuals for the five composites was performed. We used Scree plot using the pseudo T‐squared to determine the optimal number of clusters. We compared demographics, imaging biomarkers (amyloid and tau PET SUVR, hippocampal volume), plasma (pTau231, Aß40, Aß42, glial fibrillary acidic protein, and neurofilament light chain (NfL)), and cerebrospinal fluid (CSF) biomarkers (Aß42/40, NfL, Neurogranin, Visinin‐like protein, YKL‐40, and Synaptosome Associated Protein 25) across the clusters after adjusting for age, sex, and education. We compared gray matter density of each EOnonAD cluster to controls (n = 84) using voxel‐wise multiple linear regressions in SPM12, adjusting for age, sex, education, and intracranial volume.ResultScree plot using the pseudo‐T‐squared suggested three clusters. Cluster 1 (38/62, 61.3%) was characterized by having the mildest cognitive impairment in all domains. Cluster 2 (19/62, 30.6%) was characterized by more severe memory and language impairment. Cluster 3 (5/62, 8.1%) was characterized by more severe impairment in speed/attention, visuospatial, and executive function (Table 1). Cluster 3 showed significantly higher NfL for both plasma (Cluster 1 vs 3, p<0.001; Cluster 2 vs 3, p < 0.004) and CSF (Cluster 1 vs 3, p = 0.001). Other biomarkers did not show significant difference (Table 1). Only Cluster 3 showed significant atrophy in the bilateral fronto‐parietal areas at p<0.01, uncorrected (Figure 1).ConclusionWe identified heterogeneity in cognitive patterns among amnestic EOnonAD individuals. Cluster 1 had mildest cognitive impairment; Cluster 2 had predominant impairment in memory and language; and Cluster 3 had predominant impairment in speed/attention, visuospatial, and executive function, with significant fronto‐parietal atrophy and high NfL indicating active neurodegeneration.
A Machine Learning Approach to Identify Individualized Baseline MRI, Plasma, Cardiovascular and Lifestyle Predictors of a 5‐Year Cognitive Decline
Gebre, Robel K , Raghavan, Sheelakumari, Hofrenning, Ekaterina I. , Przybelski, Scott A. , Lesnick, Timothy G. , Vassilaki, Maria , Petersen, Ronald C. , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Raghavan, Sheelakumari , Knopman, David S. , Machulda, Mary M. , Jack, Clifford R. , Vemuri, Prashanthi

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.082831 Get It

AbstractBackgroundThe mapping between risk factors and biomarkers with cognitive performance and decline in the older adults is complex and varies significantly across different age and sex groups. Our goals were to (i) develop a machine learning (ML) model to predict baseline cognition and cognitive decline over a 5‐year follow‐up using only baseline assessments, and (ii) identify important modifiable and non‐modifiable predictors of cognitive decline across different age strata.MethodWe utilized longitudinal data from 2219 participants (mean age (SD): 70 (12) years, 49% male) from Mayo Clinic Study of Aging who had 43 features belonging to cardiovascular health, plasma, MRI (diffusion and structural), and lifestyle measures. Cognition was measured using a global cognition z‐score. We built ML models to predict baseline cognition and rate of cognitive decline over 5‐years (linear regression slopes over all individual followup measurements for each participant) using baseline assessments as inputs. We then built a model for each category separately and as a pooled model with all measures included, incorporating education and sex as demographic features in all models (Fig. 1). We applied a multi‐layer stack ensemble ML technique that utilized repeated k‐fold bagging to maximize accuracy. Importance of the top predictors were assessed in three age strata (55‐65 years (31%), 65‐80 years (46%), 80‐95 years (23%)).ResultThe pooled model explained the largest variance for prediction of baseline cognition and cognitive decline (Fig. 2). In individuals ≤80 years, lower NfL was most predictive of higher baseline cognition. A combination of imaging and plasma features predicted the 5‐year cognitive decline. Additionally, in individuals ≤65 years, diabetes and hypertension were important predictors of faster cognitive decline and in those >80, lower BMI and midlife physical/cognitive activity was an important predictor of faster cognitive decline (Fig. 3).ConclusionThe plasma model was best for baseline cognition prediction and imaging model was best for cognitive decline prediction. There was significant heterogeneity in important features across the age strata. In individuals >65 years, plasma GFAP was the most important predictor of cognitive decline. Our model allowed identification of key risk factors that predicted cognitive decline.
Significance of a positive tau pet scan with a negative amyloid pet scan
Robinson, Carling G. , Lee, Jeyeon , Przybelski, Scott A. , Josephs, Keith A. , Radford, Jonathan Graff, Petersen, Ronald C. , Fields, Julie A. , Lowe, Val J. , Min, Hoon-Ki Paul , Jones, David T. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Machulda, Mary M.

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.082370 Get It

AbstractBackgroundThe implications of a positive tau (T) Positron Emission Tomography (PET) with a negative beta amyloid (A) PET are not well understood. We investigated cognitive performance in participants who were positive on tau PET but negative on beta amyloid PET.MethodWe evaluated 98 participants from the Mayo Clinic Study of Aging (MCSA) and the Mayo Clinic Alzheimer’s Disease Research Center (ADRC) who were positive for Flortaucipir (FTP) and negative for PiB PET. Participants were classified as A‐ and T+ based on Standardized Uptake Value Ratios (SUVr) of FTP and PiB PET scans, and were matched 2:1 to amyloid negative and tau negative cognitively unimpaired controls from the MCSA. Cognitive test scores were compared between the combined ADRC/MCSA group and MCSA only group. We also examined clinical diagnoses in our cohort. The most common were Alzheimer’s Disease, mild cognitive impairment (MCI), Dementia with Lewy Bodies (DLB) and Frontotemporal dementia (FTD) amongst others.ResultThere were no significant differences in demographic features or PiB SUVr between groups. There were significant differences in APOE genotype between groups. In the combined ADRC/MCSA group, 25% of A‐T‐ and 13% of A‐T+ were APOE e4 carriers (p = 0.016), and in the MCSA only group, 27% of A‐T‐and 10% of A‐T+ were APOE e4 carriers (p = 0.010). In the combined ADRC/MCSA group, the A‐T+ group demonstrated lower performance than the A‐T‐ group on the Mini Mental Status Exam (MMSE) (p<0.001), Wechsler Memory Scale‐Revised Logical Memory I (p<0.001) and Logical Memory II (p<0.001), Auditory verbal Learning Test Delayed Recall (AVLT) (p = 0.004), Category fluency animals (p = 0.005), Category fluency vegetables (p = 0.021), Trailmaking test A (p<0.001), Trail making test B (p<0.001), Wechsler Adult Intelligence Scale‐IV (WAIS‐IV) (p = 0.002), and Unified Parkinson’s Disease Rating Scale part III (UPDRS III) (p = 0.003). In the MCSA only group, the A‐T+ group had lower scores on Logical Memory II (p = 0.022), AVLT delated recall (p = 0.04), and WAIS‐R block design (p = 0.035) compared to the A‐T‐group.ConclusionPositive tau PET in the absence of beta‐amyloid positivity is associated with lower cognitive performance.
Functional variations in gamma‐secretase processing of APP are critical determinants of the clinical, biomarker, and cognitive progression of autosomal dominant Alzheimer’s disease
Fitzpatrick, Colleen , Levin, Raina, Shirzadi, Zahra , Chen, Charles D., Farlow, Martin R. , Perrin, Richard J. , Johnson, Keith A. , Chhatwal, Jasmeer P. , Investigators, the Dominantly Inherited Alzheimer Network, Schultz, Stephanie A. , Liu, Lei , Schultz, Aaron P. , Bellier, Jean‐Pierre , Joseph‐Mathurin, Nelly , Benzinger, Tammie L.S. , Day, Gregory S. , Hassenstab, Jason , Jack, Clifford R. , Jucker, Mathias , Lee, Jae‐Hong , Xiong, Chengjie , Schofield, Peter William , Karch, Celeste M. , Gordon, Brian A. , McDade, Eric , Bateman, Randall J. , Sperling, Reisa Anne , Selkoe, Dennis J. , Investigators, the Dominantly Inherited Alzheimer Network

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.082318 Get It

AbstractBackgroundThe balance between production, clearance, and toxicity of Ab peptides is central to AD pathobiology. Though highly variable in terms of age of symptom onset (AAO), hundreds of pathogenic variants in Presenilin‐1 (PSEN1) cause autosomal dominant forms of AD (ADAD). PSEN1 forms the catalytic core of the γ‐secretase complex and thereby directly mediates the production of longer, aggregation‐prone Aβ peptides relative to shorter, non‐aggregating peptides. We hypothesized that the broad AAO and biomarker heterogeneity seen across ADAD would be predictable based on mutation‐specific differences in γ‐secretase function, as measured by a ratio of production of shorter vs. longer Aβ species.MethodsAβ‐37, 38, 40, 42, and 43 production was quantified from 162 unique PSEN1 variants expressed in HEK293 cells engineered to lack endogenous wild‐type PSEN1/2 (Figure 1). Prediction of AAO was carried out in 107 PSEN1 variants (characterized by Liu et al, 2022) and then replicated with a set 55 unique PSEN1 variants represented in the Dominantly Inherited Alzheimer Network (DIAN; n = 190 corresponding variant carriers with detailed cognitive and biomarker data; Figure 2).ResultsMutation‐level variations in Aβ production, including a novel composite representing γ‐secretase function (lower score = less g‐processivity), from the cellular model were highly predictive of actual AAO across the 162 mutants examined (Non‐DIAN variants [N = 107]: r = 0.71, p <2.2e‐16; DIAN variants [N = 55]: r = 0.61, p = 6.10e‐07). Our cell‐based γ‐secretase function composite was strongly associated with cerebral PiB‐PET β‐amyloid burden (B[SE] = ‐0.03[0.01], p = 4.06e‐07), MRI gray matter volume (B[SE] = 44.22[6.4], p = 5.15e‐01), cerebrospinal fluid Aβ42/40 (B[SE] = 6.3e‐04[1.5e‐04], p = 4.46e‐05) and phosphorylated tau‐217 (B[SE] = ‐0.01[0.002], p = 1.98e‐05), Clinical Dementia Rating®‐ Sum of Boxes (B[SE] = ‐0.07[0.02], p = 4.86e‐05), and Mini‐Mental State Exam (B[SE] = 0.11[.03], p = 2.17e‐04).ConclusionsBiochemical variations in γ‐secretase function across PSEN1 pathogenic variants broadly predicted the cross‐sectional clinical, cognitive, and biomarker course of ADAD, including AAO. These findings elucidate the critical link between γ‐secretase function, Aβ production, and severity of AD. The novel approach designed here also represents a tool to account for heterogeneity in ADAD clinical trials and to assess the pathogenicity of PSEN1 variants of unknown significance or with limited family history.
The Sporadic Early‐Onset Alzheimer’s Disease Signature of Regional Atrophy
Touroutoglou, Alexandra , Katsumi, Yuta , Brickhouse, Michael , Eloyan, Ani , Apostolova, Liana G. , Dickerson, Brad C., Carrillo, María C. , Rabinovici, Gil D. , Vemuri, Prashanthi

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.080543 Get It

AbstractBackgroundIn EOAD, the localization of neurodegeneration is often more prominent in posterior lateral temporal, lateral and medial parietal, frontal, or occipital cortex relative to the medial and ventral temporal cortical localization of typical LOAD. Convergently, neuropathological investigations have identified a “hippocampal‐sparing” form of AD that is often present in younger patients. For these reasons, imaging biomarkers of neurodegeneration in EOAD, such as Magnetic Resonance Imaging (MRI) measures of atrophy, likely need to be different than those of neurodegeneration in typical LOAD. Although prior neuroimaging work has advanced our understanding of anatomical abnormalities in EOAD, these studies have included small samples, most composed of amnestic EOAD dementia and none focused on developing an MRI biomarker specific to EOAD. Such a disease‐signature MRI biomarker has been established and validated in LOAD dementia and has proven to be powerful in predicting progressive decline in people with MCI or who were cognitively unimpaired and in predicting molecular biomarker status. An a priori‐defined regional atrophy signature may also be helpful in constraining the analysis of MRI data in studies of putative disease‐modifying therapies.MethodLEADS is an observational study which includes annual MRI. In this analysis, we used FreeSurfer to define the sporadic EOAD atrophy signature in a small sample of MGH EOAD patients, and investigated its reproducibility in LEADS, as well as the magnitude of atrophy and its relationship to clinical measures.ResultThe EOAD signature is robustly reproducible across the two independent patient cohorts, with prominent atrophy in caudal lateral temporal cortex, inferior parietal lobule, and posterior cingulate and precuneus cortex, with relative sparing of medial temporal lobe structures. Comparing patients to controls, Cohen’s d effect sizes within various regions ranged from 0.99 to 1.98.ConclusionThis study demonstrates the specific cortical regions with most prominent atrophy in patients with sporadic EOAD; this signature of regional atrophy will be used to examine longitudinal change.
Visual versus quantitative assessments using Pittsburgh compound‐B and Flutemetamol PET scans across age groups
Lee, Jeyeon , Przybelski, Scott A. , Lesnick, Timothy G. , Kantarci, Orhun H. , Kemp, Bradley J. , Lowe, Val J. , Zeydan, Burcu , Johnson, Derek R. , Schwarz, Christopher G. , Senjem, Matthew L. , Min, Hoon-Ki Paul , Jack, Clifford R. , Kantarci, Kejal

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.082897 Get It

AbstractBackgroundBoth 11C‐Pittsburgh compound‐B (PiB) and 18F‐Flutemetamol (FMT) have off‐target white matter (WM) signal that increases with age, but WM uptake is stronger with FMT than PiB. Although their WM patterns are comparably associated with age, the difference between them may impact visual and quantitative assessments of cortical amyloid‐β uptake. Our objective was to determine whether PiB PET and FMT PET visual assessments agree with quantitative cortical amyloid‐β evaluations.MethodA cohort of cognitively unimpaired (CU) younger adults with median (range) of 39 (30, 48) years (N = 30), CU older adults with age of 67 (61, 83) years (N = 30) and older adults with AD dementia with age of 67 (54‐84) years (N = 23) underwent MRI, PiB PET and FMT PET. PiB‐PET and FMT PET scans were evaluated visually by two nuclear medicine specialists blinded to participant information. Disagreements were reconciled with a second, joint round of visual reads. Readers applied standard visual assessment criteria using the absence of regional gray matter (GM) and WM contrast as an indication of a positive scan. The global cortical PiB standard uptake value ratio (SUVr) was obtained referencing to cerebellar crus uptake and converted to centiloid values. Participants were classified as PiB positive/negative using a centiloid cut‐off of 22.ResultPiB and FMT visual positivity agreed with quantitative positivity on PiB‐based centiloid values in 69/83 for PiB and 78/83 for FMT. There were 10 disagreements with PiB, 1 disagreement with FMT and 4 disagreements with both. Few disagreements occurred near the centiloid threshold. Interestingly, all disagreements between visual reads (amyloid‐β positive) and centiloid (amyloid‐β negative) in the CU younger were with PiB. FMT disagreements were always in the CU older and AD groups.ConclusionDisagreements between amyloid‐β positivity on visual reads and quantitative measurements (centiloid) may depend on age and tracer. PiB WM uptake is lower than FMT WM uptake, which may lead to reduced contrast between GM and WM (part of the standard criteria for visual reads), especially in younger ages. In contrast, WM uptake increases at older ages, and increased WM signal may bleed more into cortical regions, hiding subtle, near‐threshold cortical uptake, especially with FMT.
Mayo Clinic Alzheimer’s Disease Research Center Approach
Petersen, Ronald C. , Kantarci, Kejal

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S23 | Pages: No page available

10.1002/alz.078463 Get It

AbstractMayo Clinic Alzheimer’s Disease Research Center (ADRC) has been operational since 1990 supported by the US National Institutes of Health. In addition, in the aging and Alzheimer’s disease (AD) spectrum research, Mayo Clinic has been active in since 1986 with the Mayo Alzheimer’s Disease Patient Registry that evolved to the Mayo Clinic Study of Aging (MCSA) to become a population‐based study of aging and cognitive impairment in 2004.The overall goal of Mayo Clinic ADRC is to provide a structured environment that supports innovative research and enable translation aimed at accelerating the development of effective treatment and prevention for AD and related dementias at all stages of the disease. Our comprehensive ADRC is located in Rochester, Minnesota (MCR), and Jacksonville, Florida (MCF), and shares its operations in all of the Cores between the two geographic sites. ADRC core activities include the Administrative Core, Clinical Core, Data Management and Statistics Core, Neuropathology Core, Neuroimaging Core, Biomarker Core, the Outreach and Education Core (ORE Core), and the Research Education Component. ADRC Cores also interact directly with the MCSA.The theme of the center during the current cycle is “Similarities and Differences Among Neurodegenerative Disorders”. Therefore, in addition to focusing on the recruitment of participants along the AD spectrum, we continue to focus on the recruitment of persons on the frontotemporal lobar degeneration (FTLD) and the Lewy body disorders (LBD) spectra, including the prodromal stages of the neurodegenerative dementias.This focus expands on previous accomplishments of the ADRC across the neurodegenerative disease spectra. The acquisition and development of new biomarkers for the neurodegenerative diseases is a major focus of the Center, and the recruitment of research participants in all three disorders enhance randomized controlled trial studies.The Mayo ADRC interacts with other ADRCs on various collaborative efforts and supports Developmental Projects that utilize ADRC resources with the goal of attracting early‐stage and established investigators into the AD research field.
Six Year Effects of Hearing Treatment on Cognitive Decline and Dementia: Design and Statistical Considerations of the Aging and Cognitive Health Evaluation in Elders – Brain Health Follow‐Up Study
Huang, Alison , Burgard, Sheila , Gravens‐Mueller, Lisa, Mitchelle, Christine, Mosley, Thomas H., Reed, Nicholas S. , Lin, Frank R. , Pike, James Russell , Arnold, Michelle L. , Chisolm, Theresa Hnath , Couper, David , Deal, Jennifer A. , Goman, Adele M. , Hayden, Kathleen M. , Jack, Clifford R. , Pankow, James S. , Sanchez, Victoria A , Schrack, Jennifer A. , Coresh, Josef

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S23 | Pages: No page available

10.1002/alz.077301 Get It

AbstractBackgroundHearing loss is associated with cognitive decline and dementia. The ongoing ACHIEVE Study was the first randomized trial to test the effects of hearing treatment on three‐year cognitive change. The ACHIEVE – Brain Health Follow‐Up Study will extend follow‐up to six years post‐randomization to determine the long‐term and potentially nonlinear effects of hearing treatment vs. health education control with delayed treatment on dementia and cognitive decline.MethodsParticipants will be recruited from the 977 participants enrolled in the ACHIEVE Study. After Year 3, hearing intervention participants will continue to receive hearing care and the control group will be offered the hearing intervention. Co‐primary study outcomes will be cognitive decline and a composite of incident mild cognitive impairment (MCI)/probable dementia. Secondary outcomes include domain‐specific cognitive decline, brain structural changes on magnetic resonance imaging (MRI), and other functional outcomes (e.g., physical activity, social isolation). Power analyses for the co‐primary outcomes assumed an annual attrition rate of 10% and an immediate, lagged, or cumulative treatment effect.ResultsWhen comparing multi‐year cognitive decline (Table 1), in the scenario of a constant treatment effect that assumes a strong and immediate treatment effect, the benefit of extended follow‐up is not greater power, but additional information on the long‐term effects of hearing intervention. In a scenario of a lagged treatment effect, a two‐year lag in the treatment effect causes the Year 3 assessment to be severely underpowered (28%) but provides sufficient power (80%) at Year 6 despite attrition. In a scenario of a cumulative treatment effect that increases with time, analyses are similarly underpowered at Year 3 (65%) but not at Year 6 (82%). The same pattern is evident when estimating the power at Year 3 (57%) and Year 6 (80%) to detect incident MCI/probable dementia in a Cox regression model that assumes a protective hazard ratio of 0.70 (Figure 1).ConclusionAcross all non‐constant scenarios of potential treatment effect, six years of follow‐up increases precision and provides valuable information to better delineate long‐term cognitive trajectories. The ACHIEVE ‐ Brain Health Follow‐Up Study will be completed in 2025.
Physical Inactivity and Social Determinants of Health Among Older Adults with Mild Cognitive Impairment and Dementia
Bartley, Mairead M. , Baer‐Benson, Henry, Khera, Nandita , Schroeder, Darrell R. , Sauver, Jennifer L. St. , Griffin, Joan M.

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S23 | Pages: No page available

10.1002/alz.073363 Get It

AbstractBackgroundPhysical activity can improve the physical health of people living with mild cognitive impairment (MCI) and dementia and may have cognitive benefits. Identifying modifiable social factors inhibiting physical activity among this group is important. We examined the relationship between reported physical activity levels and social determinants of health (SDOH) in a population of older adults living with MCI or dementia.MethodWe included people with a diagnosis of MCI or dementia, age 55 years and older, who were empaneled to Community Internal Medicine at Mayo Clinic (Rochester, Minnesota), had a clinic visit between June 1, 2019 and June 30, 2021 and had completed a SDOH questionnaire. We focused on 8 SDOH domains: education, depression, alcohol use, stress, financial resource strain, social connections, food insecurity and transportation needs. Self‐reported activity levels were categorized as inactive (0 minutes of exercise per week), insufficiently active (10‐140 minutes per week) or sufficiently active (≥150 minutes per week). SDOH domains were compared according to physical activity level using χ2 tests and multinomial logistic regression.ResultA total of 3224 persons with MCI (n = 1371) or dementia (n = 1853) who had completed questions on physical activity were included. Of these, 1936 (60%) were characterized as physically inactive and 837 (26%) insufficiently active. Characteristics associated with an increased likelihood of physical inactivity were older age, female sex, obesity, lower education, dementia diagnosis, depression risk and increased social isolation (all p<0.001).ConclusionPhysical inactivity is common among people living with MCI and dementia. Physical activity levels may be influenced by many modifiable factors, highlighting potential areas for intervention in this population.